ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sovateltide

Also written as “Sovateltide”, “SPI-1620” and “PMZ-1620 along with standard treatment”.

Its studies are mostly in Stroke · Ischemic Stroke · Brain Injuries, Traumatic · Hypoxia-Ischemia, Brain · Spinal Cord Injuries, led by 2 companies.

Drug pageSovateltide: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 5, 202311 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharmazzits history only85 open or runningphase 4since Jul 5, 2023Jul 31, 2019Nov 2026phase 2 · NCT05514340
Zydus Lifesciences30 open or runningphase 2since Nov 27, 2012Jan 31, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Zydus Lifesciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2008First study: phase 1 study in CarcinomaFirst studyNCT00613691 · 36 enrolled · United States
  2. Nov 27, 2012Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01741155 · 34 enrolled · United States
  3. Jan 14, 2013Phase 2 study in Biliary Tract NeoplasmsNCT01773785 · 30 enrolled · United States
  4. Jun 9, 2019Named sovateltideINNProposed as its International Nonproprietary Name in WHO's List 121 · before, SPI-1620

TargetBeta

EDN1 →read by rule
“Sovateltide (PMZ-1620, IRL-1620) is a highly selective ETB receptor agonist and a synthetic analog of ET-1.”study text, by rule · the study

Studies

All 3 Zydus Lifesciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01773785Biliary Tract Neoplasms · United States2TerminatedSep 201530
NCT01741155Carcinoma, Non-Small-Cell Lung · United States2TerminatedJul 201534
NCT00613691Carcinoma · United States1CompletedJan 201236

How it is read

Names in the registry

  • “Sovateltide”, 3 entries
  • “SPI-1620”, 3 entries
  • “PMZ-1620 along with standard treatment”, 2 entries
  • “PMZ-1620 (sovateltide) along with standard treatment”, 2 entries
  • “Sovateltide along with standard treatment”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.